- Do these documents illustrate a change of course for FDA, indicate a path for the future, or leave unanswered questions?
- What are the First Amendment implications?
This webinar will discuss these questions, as well as insights on how these two draft guidance documents might be implemented and the potential effect for drug and medical device companies. The draft guidance documents are open for comment until April 19, 2017.
- +$100 for non-members
Internet Explorer and Microsoft Edge are not supported by the checkout process.
On-demand webinar recordings are sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day of your purchase.